Indivior enters sparse cannabis use disorder pipeline with $30M upfront for Aelis rights deal
There’s no one else in the pipeline, but Indivior is making a bet that Aelis Farma has what it takes to bring a cannabis use disorder therapy into the clinic with a $30 million upfront rights deal.